 |
|
Predicting Methicillin Resistance and the Effect of Inadequate Empiric Therapy on Survival in Patients With Staphylococcus aureus Bacteremia
Mary-Claire Roghmann, MD
Arch Intern Med. 2000;160:1001-1004.
Background The restriction of vancomycin hydrochloride use is recommended as a measure to decrease the emergence of vancomycin resistance in gram-positive organisms; however, vancomycin also is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. If vancomycin use is restricted to patients with documented infections due to methicillin-resistant organisms, then patients with MRSA infections may not initially receive vancomycin. This study was performed to determine factors that predict MRSA bacteremia and if ineffective empiric antibiotic therapy increased the risk of death in patients with S aureus bacteremia.
Methods We conducted a retrospective cohort study of all patients with clinically significant S aureus bacteremia (132 episodes in 128 patients) diagnosed between October 1, 1995, and January 1, 1998, at an urban acute care Veterans Affairs medical center (approximately 200 acute care beds) in Baltimore, Md. During the study period, vancomycin was a restricted antibiotic. Empiric use had to be approved by an attending physician specializing in infectious diseases.
Results Compared with patients who had methicillin-sensitive S aureus bacteremia, patients with MRSA bacteremia were significantly older (70 vs 58 years; P<.01), more likely to have a history of MRSA (47% vs 6%; P<.01) and a nosocomial infection (76% vs 50%; P<.01), and less likely to use injection drugs (8% vs 32%; P<.01). In addition, compared with patients who had methicillin-sensitive S aureus bacteremia, patients with MRSA bacteremia were significantly less likely (45% vs 98%; P<.01) to receive effective antibiotic therapy during the first 48 hours of hospitalization. However, the risk of death due to ineffective empiric therapy was less than 1 (relative risk, 0.82; 95% confidence interval, 0.36-1.88) and did not change significantly when adjusted for age, occurrence of sepsis, or nosocomial infection.
Conclusions The results of this study support the safety of the restriction of vancomycin use in patients with clinically significant S aureus bacteremia. However, patients with a history of MRSA are more likely to have future MRSA infections and should receive empiric therapy using vancomycin for possible S aureus infections, particularly for nosocomial infections.
From the Veterans Affairs Maryland Health Care System and the Division of Hospital Epidemiology, Department of Medicine, University of Maryland School of Medicine, Baltimore.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical implications of antimicrobial resistance for therapy
MacGowan and on behalf of the BSAC Working Parties on Resistanc
J Antimicrob Chemother 2008;62:ii105-ii114.
ABSTRACT
| FULL TEXT
Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome
Fang et al.
J Antimicrob Chemother 2006;57:511-519.
ABSTRACT
| FULL TEXT
Impact of Methicillin Resistance on Outcome of Staphylococcus aureus Ventilator-associated Pneumonia
Combes et al.
Am. J. Respir. Crit. Care Med. 2004;170:786-792.
ABSTRACT
| FULL TEXT
Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia
Kim et al.
J Antimicrob Chemother 2004;54:489-497.
ABSTRACT
| FULL TEXT
Rapid Molecular Diagnosis of Lactobacillus Bacteremia by Terminal Restriction Fragment Length Polymorphism Analysis of the 16S rRNA Gene
Christensen et al.
Clin Med Res 2004;2:37-45.
ABSTRACT
| FULL TEXT
Clinical Identifiers of Complicated Staphylococcus aureus Bacteremia
Fowler et al.
Arch Intern Med 2003;163:2066-2072.
ABSTRACT
| FULL TEXT
Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients
Tumbarello et al.
J Antimicrob Chemother 2002;50:375-382.
ABSTRACT
| FULL TEXT
Staphylococcus Heterogeneously Resistant to Vancomycin in China and Antimicrobial Activities of Imipenem and Vancomycin in Combination against It
Benquan et al.
J. Clin. Microbiol. 2002;40:1109-1112.
ABSTRACT
| FULL TEXT
Rapid Identification of Methicillin-Resistant Staphylococcus aureus from Positive Blood Cultures by Real-Time Fluorescence PCR
Tan et al.
J. Clin. Microbiol. 2001;39:4529-4531.
ABSTRACT
| FULL TEXT
Methicillin-Resistant Staphylococcus aureus: Comparison of Susceptibility Testing Methods and Analysis of mecA-Positive Susceptible Strains
Sakoulas et al.
J. Clin. Microbiol. 2001;39:3946-3951.
ABSTRACT
| FULL TEXT
Methicillin-Susceptible Staphylococcus aureus: Believe It, or Not
Sakoulas et al.
Arch Intern Med 2001;161:1237-1238.
FULL TEXT
Does Adequacy of Empiric Therapy for MRSA Bacteremia Matter?
JWatch Infect. Diseases 2000;2000:4-4.
FULL TEXT
|
